Sugi Predict

Sugi Predict / Compounds / SCHEMBL4833664

SCHEMBL4833664

SCHEMBL4833664

Cc1ccc([N+](=O)[O-])cc1NC(=O)c1cccc(CCl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ KMT2A Q03164 5/20 0.61
▸ HPGD P15428 1/20 0.59
▸ MEN1 O00255 2/20 0.57
▸ PABPC1 P11940 1/20 0.57
▸ DUSP3 P51452 1/20 0.57
▸ PTPN5 P54829 1/20 0.57
▸ PTPN11 Q06124 1/20 0.57
▸ EIF4H Q15056 1/20 0.57
▸ CTDSP1 Q9GZU7 1/20 0.57
▸ LMNA P02545 3/20 0.57
▸ ALDH1A1 P00352 4/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ MAPT P10636 2/20 0.56
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ PKM P14618 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7674600 0.87 KMT2A (0.56) SMN1; SMN2KMT2AMEN1PABPC1DUSP3
SCHEMBL6476512 0.87 HTT (0.74) HTTSMN1; SMN2KMT2AHPGDLMNA
SCHEMBL6396133 0.82 KMT2A (0.85) HTTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL4831878 0.81 WDR5 (0.60) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL8417009 0.80 KMT2A (0.60) HTTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL24233277 0.79 SMN1; SMN2 (0.70) HTTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL6482600 0.79 MAPK14 (0.56) KMT2AHPGDMEN1ALDH1A1RAB9A
SCHEMBL28012109 0.76 KMT2A (0.68) SMN1; SMN2KMT2AHPGDMEN1ALDH1A1
SCHEMBL29961312 0.76 HTT (0.82) HTTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL7994463 0.76 MAPT (0.56) HTTSMN1; SMN2KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442704-B2 Amide derivatives ASTRAZENECA AB (SE) 2008-10-28 — — US disclosed
US-7332483-B2 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease ASTRAZENECA AB (SE) 2008-02-19 — — US disclosed
US-20060281734-A1 Amide derivatives BROWN DEARG S 2006-12-14 — — US disclosed
US-7008945-B1 Amide derivatives ASTRAZENECA AB (SE) 2006-03-07 — — US disclosed
US-6956037-B2 Benzamide derivatives for the treatment of diseases mediated by cytokines ASTRAZENECA AB (SE) 2005-10-18 — — US disclosed
US-6686467-B2 INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 ZENECA LIMITED (GB) 2004-02-03 — — US disclosed
US-20030212068-A1 Benzamide derivatives for the treatment of diseases mediated by cytokines ASTRAZENECA AB 2003-11-13 — — US disclosed
US-20030166730-A1 Amide derivatives for the treatment of diseases mediated by cytokines ZENECA LIMITED 2003-09-04 — — US disclosed
US-6579872-B1 Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide ASTRAZENECA AB (SE) 2003-06-17 — — US disclosed
US-6498274-B1 Amide derivatives for the treatment of diseases mediated by cytokines ZENECA LIMITED (GB) 2002-12-24 — — US disclosed
CN-1319092-A Benzamide derivatives and their use as cytokine inhibitors ASTRAZENECA AB (SE) 2001-10-24 — — CN disclosed
EP-1115707-A1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-07-18 — — EP disclosed
CN-1300278-A Benzamide derivatives for the treatment of diseases caused by cytokines ASTRA ZENECA LTD (SE) 2001-06-20 — — CN disclosed
EP-1077931-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES AstraZeneca AB (SE) 2001-02-28 — — EP disclosed
CN-1271279-A Amide derivatives for the treatment of diseases mediated by cytokines ZENECA LTD (GB) 2000-10-25 — — CN disclosed
WO-2000055153-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2000-09-21 — — WO disclosed
EP-1017378-A1 AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES AstraZeneca UK Limited (GB) 2000-07-12 — — EP disclosed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 — — WO disclosed
WO-1999059959-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ASTRAZENECA AB (SE) 1999-11-25 — — WO disclosed
WO-1999015164-A1 AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ZENECA LIMITED (GB) 1999-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212068-A1 Benzamide derivatives for the treatment of diseases mediated by cytokines IL2, IL6, IL6ST HTT 1731/4885SMN1; SMN2 2568/4885KMT2A 2107/4885
US-20060281734-A1 Amide derivatives IL6, IL6ST, IL1B HTT 2632/4885SMN1; SMN2 2166/4885KMT2A 2740/4885
US-20030166730-A1 Amide derivatives for the treatment of diseases mediated by cytokines IL2, IL6, IL6ST HTT 2083/4885SMN1; SMN2 3211/4885KMT2A 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.